Comprehensive Genomic Panel Broadens Community Oncology Treatment Options
Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network [Mar 9, 2026] La Porte et al. @DrEzraCohen @JCOPO_ASCO https://t.co/tDi3kbxdvX #PrecisionMedicine #hemeonc @TempusAI https://t.co/6QKo7c3oH2
FDA Accuses Amgen of Data Manipulation; Erasca Falls
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results https://t.co/UbftjXwEwa $AMGN $ERAS - 53% $RCKT $JANX
People Dramatize Painless At‑home Subcutaneous Injections
How YTE longs talk when they’re telling you how harrowing it is to self administer a painless at home subcutaneous injection: https://t.co/ydNEINxwLD
AI Reads Retinal Images to Screen Multiple Diseases
What superhuman vision can detect from the retinal photo, which human eyes cannot, is stunning. A new foundation AI model screening for diabetes hypertension, hyperlipidemia, gout, osteoporosis, and thyroid disease @NatureMedicine https://t.co/GhKvUqz4Vy https://t.co/iKcXCbLceu
Literate Programming Ensures Reproducible Bioinformatics Analyses
1/15 If your bioinformatics analysis isn't reproducible, it hurts science. Literate programming fixes this. Here's how to do it right 🧵 https://t.co/f06AXPUbpW
Anthocyanins Improve Cardiometabolic and Anti‑
Anthocyanin supplementation in adults at risk for dementia: a randomized controlled trial on its cardiometabolic and anti-inflammatory biomarker effects https://t.co/tHwVYQ3yvQ https://t.co/cxiRpkIj7W
Coultreon Secures $125M to Test Former Galapagos Immune Drug
Coultreon banks $125M to support testing of former Galapagos immune drug https://t.co/PUsEu2i7Vv by @Lilah_Alvarado $GLPG #biotech #startups
GLP‑1 Therapy Shows Benefit for Type 1 Diabetes Patients
A 174,000-patient analysis just delivered the first hard evidence that GLP-1 drugs work in a population every clinical trial has excluded. As a medical school professor, I teach that Type 1 diabetes is autoimmune, Type 2 is metabolic. But the cardiovascular...
Low‑cost Vaccines Delivered, Autism Genes
What a dishonest & ignorant thing to write, I develop low-cost vaccines for global health, 100 million doses administered, without patenting the technology. Also as I’ve detailed we’ve learned a lot about the genetic basis of autism, >100 autism genes,...
AstraZeneca's Bretzi Inhaler Cleared for Asthma in Teens
#AZN Bretzi inhaler approved by US FDA for treating patients 12 years old and upwards for Asthma, following the KALOS and LOGOS Phase III trials. Previously got COPD approval.
Morgan Stanley Flags IL‑23 Combos, Seeks Novel MOAs
Immunology combination studies from Morgan Stanley ahead of DUET data next week. These are mainly coformulations of established drugs, it would be more intriguing to see novel MOAs added to an IL23 backbone. https://t.co/dde8MpBhUR
Enhanced Exosomes Modulate OA Inflammatory Microenvironment
The role of exosomes and their enhancement strategies in the treatment of osteoarthritis "This article provides a comprehensive review and update on the research of exosomes, a type of extracellular vesicle, in the treatment of OA by modulating the inflammatory microenvironment..." https://t.co/xHjTCixJNE
TB‑500 Is Not TB‑4: No Human Evidence
TB - 500 is a short chain fragment synthesized from Thymosin Beta-4. TB-4 has solid human evidence for use. TB500 has absolutely no evidence. Totally different compounds. They cannot be referred to interchangeably because they simply are NOT the same
Breakthrough Prize Showcases Baby Gene‑Editing Miracle
The 2026 Breakthrough Prize ceremony (“the Oscars for science”) celebrated the achievements of many remarkable scientists and their students and collaborators last weekend. Here’s the video of the show: https://t.co/eCHUnDqrYX. And here’s the segment in which Anne Hathaway and Alex...
Balanced Longevity Research Shows Real Human Impact
Longevity Science Is Overhyped. But This Research Really Could Change Humanity. We were delighted to have @susandominus with us at the last academy meeting earlier this year. She does gives a balanced take on the latest rejuvenation science. This...
10x Genomics Unveils A
I've been watching spatial biology for years. What @10xGenomics just announced changes the game. Serge Saxonov, CEO and Co-founder, 10x Genomics told Synbiobeta, "Biology is inherently complex, and as much progress as we have made, we still understand only a...
Traditional MDs Now Seeking Peptide Knowledge for Joint Health
So many of my “conventional” (not in the health and wellness space or even online much) MD friends are asking about peptides to 1) get educated (patients are asking them about peptides) 2) they want to know if BPC can help their...
From Trial‑and‑Error to Predictive Cell‑Fate Engineering
We’re still engineering biology by trial and error. SynBioBeta 2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ18mc @MichaBreakstone is building a model to predict cell fate with his new...
Cellular Rejuvenation Could Shift Medicine to Youthful Resilience
Cellular rejuvenation may redefine medicine—not by treating disease, but by restoring youthful resilience at the cellular level. But science, safety, and hype are colliding. Worth the read (gift link) : 👇 https://t.co/7JGNdhFsFP via @NYTimes
Lithium Interaction Poses Major Seizure Risk with Psilocybin
Most physicians were never taught psilocybin in medical school. Their patients in three states can now legally access it. Oregon's program has been operating since summer 2023. Colorado's healing centers came online in 2025. New Mexico passed its Medical Psilocybin...
Autologous iPSC Dopamine Cells Boost Parkinson’s Function without Immunosuppression
I’ve been following @jeannefrances's work for years, and what @AspenNeuro just reported out of Copenhagen is the kind of result that changes a field. Twelve months after receiving their own reprogrammed dopamine neurons, eight Parkinson's patients are showing real, measurable...
Elliot Hershberg Returns to Lead AI Protein Dynamics Session
Why has @ElliotHershberg been coming to @SynBioBeta for the past 4 years in a row?? Elliot is a Partner at @AmplifyPartners and one of the sharpest minds at the intersection of biology and capital. He'll be moderating one of the...
Watch SynBioBeta2026 Live Anywhere, No Travel Needed
Visas. Travel costs. Time away from the lab or the office. Not everyone can make it to San Jose for #SynBioBeta2026 That's exactly why we built the livestream. 160+ sessions. 200+ speakers. Three days of Main Stage content streaming directly to your...
ERAS-0015 Linked to Fatal Pneumonitis After Care Withdrawal
$ERAS safety update, from tonight's slides. One Grade 3 TRAE of pneumonitis progressed to Grade 5 after withdrawal of supportive care per patient decision. The patient was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma who received 24 mg of ERAS-0015. The patient had...
Over Half of Gray Market Peptides Fail Quality Standards
New pre-print on gray market peptides using @finnrick_tests data: 41.6% to 71.1% of gray market peptide samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in 15% of samples. @Krysia830073
NIH Studies Often Ignore Sex Differences, Hindering Precision Medicine
Less than half of NIH-funded health studies analyze results by sex, potentially overlooking critical differences that impact diagnosis, treatment, and drug development for both men and women. precisionmedicine
Low Post‑Surgery Klotho Predicts Inflammation and Cognitive Decline
Lower levels of the anti-aging protein Klotho after surgery were strongly linked to higher inflammation and worse cognitive function in patients with postoperative cognitive dysfunction (POCD). This suggests Klotho could be a useful early biomarker—and possibly a treatment target—for predicting...
Erasca Shows Promising 40% PDAC, 62% NSCLC Responses
$ERAS Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy $RVMD 40% uORR in PDAC; 62% uORR in NSCLC https://t.co/90BkD7tBeN
Longevity Hype Outpaces Evidence; Cancer Risk Remains
This @NYTmag article on longevity science, reversing aging with cellular reprogramming, by @susandominus, is over the top. We have no proof that rejuvenation of a human organ is possible, no less the whole body, and there is risk of inducing...
NTLA Turns Red, Faces Cash‑Raise Dilemma
$NTLA finally red. Took longer than I expected. How do they raise the cash they need from here? Are they going to be forced to take on debt?
Future Antidepressant Could Transform Millions Like Tirzepatide
Imagine a drug for reducing depression or anxiety that is as powerful as Tirzepatide is for reducing hunger. I think tens of millions of people will be on drugs like this in the next 5 years and I think it...
Eli Lilly Acquires Ajax to Strengthen JAK Pipeline
Lilly to buy startup Ajax in bid for a better JAK drug https://t.co/RMQQZ4mRFG $INCY $BMY $LLY $TAK #biotech #startups
Dispatch Biotherapeutics Launches First Clinical Trial
Remember Car June's new venture, Dispatch Biotherapeutics (raised $216 m since 2022)? Here's its first clinical trial: https://t.co/EIrZHSeHT8
Score Single-Cell Pathways with ssGSEA, GSVA, AUCell, UCell
1/15 Want to decode pathway activity in single cells? Understand ssGSEA, GSVA, AUCell, and UCell—tools that score gene sets per cell. Here's how they work 🧵 https://t.co/FIOA8YHBcl
Digital Twins Will Accelerate Drug Development via Virtual Trials
How digital twins and in silico clinical trials can change the future of drug development https://t.co/lEhJNwrSlH
ERAS Pan‑Ras Data Released; RVMD Alleges Patent Infringement
$ERAS pan-Ras data update this afternoon after market close. also, $RVMD sent Erasca a letter claiming ERAS-0015 violates certain RevMed patents. https://t.co/QTmyUhT89n
Don't Reinvent Broken Wheels—Use Existing Bioinformatics Tools
1/ Bioinformaticians: Before you heroically code your own method... STOP. You might be about to reinvent a very broken wheel. https://t.co/c4FT7VXeM6
T‑cell Engagers Need Missing Design Tricks for Success
With the rise and rise of ADCs, T cell engagers have taken something of a back seat of late. What if the bigger problem is some of them may be missing a key trick? Here we highlight some design...
NTLA's HAE Results Fall Short, Funding Needed for Weak Launch
$NTLA HAE study results were both expected and unimpressive relative to current treatments. The company will need to raise a lot of money to sell a therapy that is not going to launch well.
Biosimilar T
Me writing scripts to completely control 90% of my psoriasis patients with biosimilar Taltz >2 years before $ORKA even reads out P3: https://t.co/TVaA10pHOe
Unverified Tips Can Mislead: False Compass Data
Interesting side note on today's disappointing $CMPX results: Yesterday, I received a message on Signal from someone claiming to be a Compass employee. He gave me the purported tovecimig PFS and OS data. I didn't do anything with the supposedly material...
Chromosomal Abnormalities Impact Myeloma Survival Differently Across Populations
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma [Jan 31, 2025] Bei Wang et al. @Bloodneoplasia https://t.co/IFPgCwpGo6 #mmsm #PrecisionMedicine #cancerdisparities https://t.co/vpNoEupRPG
Fathom Therapeutics Secures $47M Series A for AI‑Physics Drug Discovery
Exclusive: Fathom Therapeutics, formerly Atommap, has raised a $47M Series A, building a pipeline with its strategy of blending AI and physics approaches to drug discovery: https://t.co/iAlmJwCQK7
CRISPR Therapy Cuts Swelling Attacks 87%, 60% Attack‑Free
$NTLA Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial Attack rates dropped 87%, relative to placebo. Just over 60% were entirely attack-free over the period, compared to 11% for the placebo patients. https://t.co/ljPC7Lww0D via @Jasonmmast
NTLA's Attack Metrics Fall Short of Expectations
$NTLA 87% attack reduction and only 62% attack free rate. Attack free rate especially widely missed the bar set ahead of time by @GeneInvesting. Legitimately worse than I expected. https://t.co/wmNFYfsQSj
Oruka's Long-Acting Psoriasis Drug Achieves 63% PASI‑100
$ORKA Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study 63% PASI 100 score at 16 weeks, very strong data. https://t.co/RJxnbuU0e3 via me
Veradermics' Hair Loss Drug Clears Late-Stage Trial
Ok, here we go... $MANE Veradermics' hair loss drug succeeds in late-stage trial. A report from @ADeAngelis_bio https://t.co/jtSB36sPGO
Key Insights Await From Tovecimig Companion-002 Data
$CMPX data from Companion-002 study of tovecimig coming before 8am ET today. What to look out for, via @ByMadeleineA -> https://t.co/6IDCqMyNPE
FDA Approves Weekly Self‑Injectable Saphnelo for Lupus
#AZN Saphnelo for treating systemic lupus erythematosus, approved by US FDA for self-administration via a once a week autoinjector Pen.
Swedish Clinic Finds Limited Eligibility for New Alzheimer Drugs
Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic https://t.co/H3TgYvgVSk